Parexel Introduces Expert Series—New Medicines, Novel Insights
Parexel has announced the launch of a new expert series, New Medicines, Novel Insights. The series will feature insights from the company’s global, cross-functional experts analyzing trends impacting drug development and offering evidence-based guidance to the biopharmaceutical industry.
The inaugural report—Advancing Rare Disease Drug Development—explores the unique regulatory, scientific, and market access challenges surrounding rare disease drug development and shares best practices to address them.
To view the full New Medicines, Novel Insights: Advancing Rare Disease Drug Development report and subscribe to receive future reports, visit the interactive experience.
Reference
Parexel Introduces Expert Series – New Medicines, Novel Insights. (2023, February 28). GlobeNewswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
